Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases

$2bn Deal With $1.8bn Up Front For Idhifa Rights, Tibsovo And More

 
• By Mandy Jackson
  
Business reengineering
Agios will focus entirely on genetic diseases after selling its cancer drugs
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business